SG11201705450SA - Bacteria-comprising compositions and methods of using the same for treating and/or preventing gastrointestinal, metabolic and/or other diseases - Google Patents
Bacteria-comprising compositions and methods of using the same for treating and/or preventing gastrointestinal, metabolic and/or other diseasesInfo
- Publication number
- SG11201705450SA SG11201705450SA SG11201705450SA SG11201705450SA SG11201705450SA SG 11201705450S A SG11201705450S A SG 11201705450SA SG 11201705450S A SG11201705450S A SG 11201705450SA SG 11201705450S A SG11201705450S A SG 11201705450SA SG 11201705450S A SG11201705450S A SG 11201705450SA
- Authority
- SG
- Singapore
- Prior art keywords
- metabolic
- bacteria
- diseases
- compositions
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/1203—Addition of, or treatment with, enzymes or microorganisms other than lactobacteriaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15150701 | 2015-01-09 | ||
| PCT/EP2016/050310 WO2016110585A1 (en) | 2015-01-09 | 2016-01-08 | Bacteria-comprising compositions and methods of using the same for treating and/or preventing gastrointestinal, metabolic and/or other diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201705450SA true SG11201705450SA (en) | 2017-07-28 |
Family
ID=52434520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201705450SA SG11201705450SA (en) | 2015-01-09 | 2016-01-08 | Bacteria-comprising compositions and methods of using the same for treating and/or preventing gastrointestinal, metabolic and/or other diseases |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11452746B2 (en) |
| EP (1) | EP3242957B1 (en) |
| KR (1) | KR20170103920A (en) |
| CN (1) | CN107405369A (en) |
| AU (1) | AU2016205975B2 (en) |
| BR (1) | BR112017014649A2 (en) |
| CA (1) | CA2973285C (en) |
| DK (1) | DK3242957T3 (en) |
| ES (1) | ES2796355T3 (en) |
| PL (1) | PL3242957T3 (en) |
| RU (1) | RU2017126666A (en) |
| SG (1) | SG11201705450SA (en) |
| WO (1) | WO2016110585A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6868562B2 (en) | 2014-10-31 | 2021-05-19 | ペンデュラム セラピューティクス， インコーポレイテッド | Methods and compositions for microbial treatment and diagnosis of disorders |
| BR112017014649A2 (en) | 2015-01-09 | 2018-03-13 | Wageningen Universiteit | "human intestinal isolate and composition" |
| ES2865477T3 (en) | 2016-02-25 | 2021-10-15 | Caelus Pharmaceuticals B V | Compositions and methods for the prevention and / or treatment of vitamin B12 deficiency |
| JP2020532515A (en) | 2017-08-30 | 2020-11-12 | ペンデュラム セラピューティクス， インコーポレイテッド | Methods and compositions for the treatment of microbiome-related disorders |
| WO2019113023A1 (en) * | 2017-12-04 | 2019-06-13 | The BioCollective, LLC | Probiotics and methods of use |
| FR3085963A1 (en) * | 2018-09-19 | 2020-03-20 | Novolyze | DRY COMPOSITION OF MODEL MICROORGANISMS |
| NL2024569B1 (en) * | 2019-12-24 | 2021-09-06 | Univ Wageningen | Bacterium comprising myo-inositol to propionate pathway |
| RU2734718C1 (en) * | 2019-12-31 | 2020-10-22 | Федеральное государственное бюджетное научное учреждение "Институт экспериментальной медицины" (ФГБНУ "ИЭМ") | Method of reducing manifestation of non-motor symptoms in patients with parkinson's disease |
| NL2028324B1 (en) | 2021-05-28 | 2022-12-12 | Caelus Pharmaceuticals B V | Insulin-sensitizing agent and butyrate-producing bacterium |
| WO2023121955A1 (en) * | 2021-12-20 | 2023-06-29 | Tainnovation Inc. | The methods of and compositions for treating obesity, obesity-related diseases or cancers using a n6-methyllysine/l-lysine mixture |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2358746T3 (en) | 2004-12-28 | 2011-05-13 | Meiji Seika Kaisha Ltd. | NEW CEPA THAT CONFERTS THERAPEUTIC PROPERTIES TO THE COMPOSITIONS OF BONE AND BACTERIAL CELLS. |
| JP6116568B2 (en) | 2011-08-30 | 2017-04-19 | アカデミッシュ メディッシュ セントラム | Method for preventing and / or treating insulin resistance |
| US20140242654A1 (en) | 2013-02-26 | 2014-08-28 | Coskata, Inc. | Butyrate Producing Clostridium species, Clostridium pharus |
| WO2014150094A1 (en) | 2013-03-15 | 2014-09-25 | University Of Florida Research Foundation, Inc. | Butyrogenic bacteria as probiotics to treat clostridium difficile |
| BR112017014649A2 (en) | 2015-01-09 | 2018-03-13 | Wageningen Universiteit | "human intestinal isolate and composition" |
-
2016
- 2016-01-08 BR BR112017014649-5A patent/BR112017014649A2/en not_active Application Discontinuation
- 2016-01-08 CN CN201680005423.XA patent/CN107405369A/en active Pending
- 2016-01-08 EP EP16700202.1A patent/EP3242957B1/en active Active
- 2016-01-08 RU RU2017126666A patent/RU2017126666A/en not_active Application Discontinuation
- 2016-01-08 WO PCT/EP2016/050310 patent/WO2016110585A1/en active Application Filing
- 2016-01-08 AU AU2016205975A patent/AU2016205975B2/en active Active
- 2016-01-08 ES ES16700202T patent/ES2796355T3/en active Active
- 2016-01-08 KR KR1020177022306A patent/KR20170103920A/en not_active Application Discontinuation
- 2016-01-08 SG SG11201705450SA patent/SG11201705450SA/en unknown
- 2016-01-08 US US15/542,311 patent/US11452746B2/en active Active
- 2016-01-08 PL PL16700202T patent/PL3242957T3/en unknown
- 2016-01-08 CA CA2973285A patent/CA2973285C/en active Active
- 2016-01-08 DK DK16700202.1T patent/DK3242957T3/en active
-
2020
- 2020-09-23 US US17/030,196 patent/US11426436B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN107405369A (en) | 2017-11-28 |
| KR20170103920A (en) | 2017-09-13 |
| CA2973285C (en) | 2023-10-17 |
| RU2017126666A (en) | 2019-02-12 |
| US20210069263A1 (en) | 2021-03-11 |
| AU2016205975A1 (en) | 2017-07-27 |
| RU2017126666A3 (en) | 2019-07-24 |
| US11452746B2 (en) | 2022-09-27 |
| WO2016110585A1 (en) | 2016-07-14 |
| US20180353552A1 (en) | 2018-12-13 |
| AU2016205975B2 (en) | 2021-05-27 |
| US11426436B2 (en) | 2022-08-30 |
| CN107405369A8 (en) | 2018-01-16 |
| CA2973285A1 (en) | 2016-07-14 |
| EP3242957B1 (en) | 2020-03-11 |
| EP3242957A1 (en) | 2017-11-15 |
| BR112017014649A2 (en) | 2018-03-13 |
| ES2796355T3 (en) | 2020-11-26 |
| DK3242957T3 (en) | 2020-06-02 |
| PL3242957T3 (en) | 2020-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL264049A (en) | Compounds, compositions, and methods for the treatment of disease | |
| HK1258205A1 (en) | Compositions and methods for the treatment of hemoglobinopathies | |
| IL264156A (en) | Compounds, compositions, and methods for the treatment of disease | |
| HK1256726A1 (en) | Carrier-binding agent compositions and methods of making and using the same | |
| IL259246A (en) | Compositions of therapeutic substances, methods and uses thereof | |
| IL289099A (en) | Methods for the storage of whole blood, and compositions thereof | |
| SG11201705450SA (en) | Bacteria-comprising compositions and methods of using the same for treating and/or preventing gastrointestinal, metabolic and/or other diseases | |
| HK1259372A1 (en) | Therapeutic compounds, compositions and methods of use thereof | |
| EP3408344A4 (en) | Well treatment methods and compositions | |
| EP3310376A4 (en) | Modified therapeutic agents and compositions thereof | |
| PT3261726T (en) | Composition for the treatment of acne | |
| ZA202104969B (en) | Compositions comprising 15-hepe and methods of using the same | |
| EP3182989A4 (en) | Methods and compositions for the prevention and treatment of disease | |
| IL266047A (en) | Methods and compositions for the treatment of fabry disease | |
| IL275182A (en) | Compositions and methods for the treatment of metabolic conditions | |
| HK1249515A1 (en) | Methods and compositions for the prevention and treatment of hearing loss | |
| IL249640A0 (en) | Compositions for the treatment of epistaxis | |
| ZA201902781B (en) | Compositions and methods for the treatment of xerostomia | |
| IL248210A0 (en) | Methods and compositions for the treatment of vascular malformation | |
| HK1247136A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
| EP3341006A4 (en) | Compositions and methods for the treatment of neurodamage | |
| HK1255695A1 (en) | Composition and methods for the treatment of blepharoptosis | |
| HK1258999A1 (en) | Compositions, methods, and medical compositions for treatment of and maintaining the health of the liver | |
| HK1258765A1 (en) | Therapeutic compounds, compositions and methods of use thereof | |
| ZA201802201B (en) | Novel formulation and treatment methods |